Nutrition Disorders: Clinical Trials

875 trials for Nutrition Disorders, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

567 completed, 105 recruiting, 52 active not recruiting, 45 unknown. 875 Phase 1, 176 Phase 2.

By phase and status

PhaseTrialsStatus
Phase 1875Completed 567, Recruiting 105, Active not recruiting 52, Unknown 45, Not yet recruiting 44, Terminated 39, Withdrawn 20, Suspended 2, Enrolling by invitation 1
Phase 2176Completed 109, Recruiting 19, Unknown 15, Active not recruiting 11, Terminated 9, Withdrawn 6, Not yet recruiting 4, Suspended 2, Enrolling by invitation 1

Follow Nutrition Disorders: new trials by email Literature Review of Nutrition Disorders trials Research Report on Nutrition Disorders

Trials (filtered) newest first · largest first

All 875 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Human Models of Selective Insulin Resistance: Pancreatic Clamp
Insulin human, Octreotide Acetate, Glucagon - Insulin Resistance, Hyperinsulinemia
Phase 1Not yet recruitingColumbia University362027-01-012026-02-06
Evaluation of Superiority of Valsartan+Celecoxib+Metformin Over Metformin Alone in Type 2 Diabetes Patients
Metformin, Val, Cel and Met XR Low, Val, Cel and Met XR High - Type 2 Diabetes, High Blood Pressure
Phase 1 / Phase 2WithdrawnARKAY Therapeutics2026-12-102026-07-16
A Study to Compare How Survodutide is Taken up by the Body When Given in 2 Formulations to People With Overweight or Obesity
Survodutide formulation A, Survodutide formulation D1 - Healthy, Obesity
Phase 1Not yet recruitingBoehringer Ingelheim802026-12-032026-11-16
A Study to Evaluate a Single Dose of IBIO-610 in Participant With Obesity.
IBIO-610, Placebo - Obesity & Overweight
Phase 1Not yet recruitingiBio, Inc.322026-12-012026-10-22
Glucagon-Like Peptide-1 Receptor Agonists to Attenuate Metabolic Risk in Individuals With Duchenne Muscular Dystrophy
Semaglutide (Rybelsus®), Placebo - Duchenne Muscular Dystrophy (DMD)
Phase 1 / Phase 2RecruitingVanderbilt University Medical Center302026-12-012026-11-12
Investigating the Effects of 24 Hour LEAP2 Infusion in Individuals With Overweight and Obesity
Liver-expressed antimicrobial peptide 2, Placebo - Obesity & Overweight
Phase 1 / Phase 2Not yet recruitingUniversity Hospital, Gentofte, Copenhagen182026-11-302026-10-27
A Phase I Clinical Trial of the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Food Effect of UBT48128 Tablets in Healthy Participants
UBT48128, Placebo - Overweight , Obesity
Phase 1Not yet recruitingThe United Bio-Technology (Hengqin) Co., Ltd.602026-11-292026-11-06
Study of IPG1094 Tablets in Chinese Healthy Adults and Obese Adults
IPG1094 Tablet and matching Placebo - Healthy Volunteers; Obesity
Phase 1Not yet recruitingNanjing Immunophage Biotech Co., Ltd722026-11-252026-11-13
A Phase I Study to Evaluate Single and Multiple Subcutaneous Administrations of QLS2406-1 Injection in Chinese Adult Participants With Overweight and Obesity.
QLS2406-1 injection, Placebo - Overweight and Obesity, MASH - Metabolic Dysfunction-Associated Steatohepatitis
Phase 1Not yet recruitingShanghai Qilu Pharmaceutical Research and Development Center LTD1242026-11-202026-11-16
A Study of Zovaglutide (ZT002 Injection) in Participants With Hepatic Impairment and Healthy Participants
Zovaglutide - Overweight, Obesity
Phase 1Not yet recruitingBeijing QL Biopharmaceutical Co.,Ltd242026-11-132026-11-04
Comparing the Extent to Which Maridebart Cafraglutide is Made Available in the Body of Participants Living With Overweight or Obesity After Switching From Glucagon-like Peptide-1 Receptor Agonists (GLP-1RA)
Maridebart cafraglutide - Obesity, Overweight
Phase 1RecruitingAmgen1802026-11-132026-11-02
Comparing the Extent to Which Maridebart Cafraglutide (AMG 133) is Made Available in the Body When Administered Using Two Subcutaneous Presentations After Multiple Doses
Maridebart cafraglutide - Obesity, Overweight
Phase 1Not yet recruitingAmgen3562026-11-092026-11-06
A Trial to Assess the Relative Bioavailability of Different Subcutaneous Formulations of AZD9550 and AZD6234
AZD9550 solution for injection, AZD6234 solution for injection, Formulation 1 solution for injection - Healthy Participants
Phase 1Not yet recruitingAstraZeneca602026-11-092026-11-02
A Phase I Study to Evaluate the Food Effect on Ecnoglutide Tablet
Dose 1, Dose 2 - Food Effect in Healthy Volunteers, Weight Management
Phase 1Not yet recruitingHangzhou Sciwind Biosciences Co., Ltd.722026-11-032026-11-13
Pharmacokinetics, Safety, and Tolerability of DA-302168S Tablets in Participants With Varying Degrees of Renal Impairment and Normal Renal Function
DA-302168S - Obesity & Overweight
Phase 1RecruitingChendu DIAO Pharmaceutical Group CO., LTD.322026-11-022026-11-16
A Study of LY4247147 in Participants With Obesity or Overweight Who Are Otherwise Healthy
LY4247147, Placebo - Obesity, Overweight
Phase 1Not yet recruitingEli Lilly and Company1082026-11-012026-11-04
Brain Dopamine Dynamics in Obesity
Milkshake, NeuroEXPLORER, [11C]raclopride - Obesity
Phase 1Not yet recruitingYale University1002026-11-012026-11-04
A Study to Investigate the Effect of Injection Site and Ethnicity on KAI-4729 Pharmacokinetics in Non-Asian and Asian Participants Living With Obesity or Overweight
KAI-4729 - Overweight or Obesity
Phase 1Not yet recruitingKailera602026-11-012026-11-09
A Study to Learn How Different Amounts of the Study Medicine Called PF-08656795 Are Tolerated and Act in Adults With Overweight or Obesity
Placebo, PF-08656795 - Overweight and/or Obesity
Phase 1Not yet recruitingPfizer1502026-10-302026-10-15
Pharmacokinetics, Safety, and Tolerability of DA-302168S Tablets in Participants With Hepatic Impairment and Normal Hepatic Function
DA-302168S - Obesity, Overweight, T2DM (Type 2 Diabetes Mellitus)
Phase 1Not yet recruitingChendu DIAO Pharmaceutical Group CO., LTD.322026-10-222026-10-15

Showing 20 of 875. Sign in to see all of them.

Narrower conditions

Obesity (733)  ·  Overweight (336)  ·  Diabetes Mellitus, Type 2 (89)  ·  Insulin Resistance (39)  ·  Weight Loss (38)  ·  Diabetes Mellitus (36)  ·  Vitamin D Deficiency (35)  ·  Metabolic Syndrome (23)  ·  Non-alcoholic Fatty Liver Disease (23)  ·  Hypertension (20)  ·  Motor Activity (19)  ·  Body Weight (16)  ·  Obesity, Morbid (16)  ·  Metabolic Diseases (15)

Broader conditions

Nutritional and Metabolic Diseases (874)  ·  Pathological Conditions, Signs and Symptoms (808)  ·  Overnutrition (798)  ·  Signs and Symptoms (794)  ·  Body Weight (777)  ·  Overweight (465)  ·  Metabolic Diseases (184)  ·  Glucose Metabolism Disorders (162)  ·  Endocrine System Diseases (132)  ·  Diabetes Mellitus (89)  ·  Malnutrition (63)  ·  Deficiency Diseases (60)  ·  Avitaminosis (59)  ·  Hyperinsulinism (49)

Interventions

semaglutide (35)  ·  Cholecalciferol (19)  ·  Acetaminophen (18)  ·  Tirzepatide (17)  ·  Sodium Chloride (16)  ·  Metformin (15)  ·  Liraglutide (12)  ·  Rosuvastatin Calcium (12)  ·  BI 456906 (11)  ·  Vitamin D (11)  ·  cagrilintide (10)  ·  Exercise (9)  ·  Warfarin (9)  ·  Atorvastatin (8)  ·  Digoxin (8)

Sponsors

Novo Nordisk A/S (86)  ·  Eli Lilly and Company (40)  ·  Pfizer (31)  ·  AstraZeneca (24)  ·  Amgen (17)  ·  Boehringer Ingelheim (17)  ·  Mayo Clinic (14)  ·  Vanderbilt University Medical Center (14)  ·  GlaxoSmithKline (10)  ·  Columbia University (9)  ·  University of Pittsburgh (9)  ·  BrightGene Bio-Medical Technology Co., Ltd. (8)  ·  Shanghai Minwei Biotechnology Co., Ltd (8)  ·  Stanford University (8)  ·  Yale University (8)

Countries

United States (450)  ·  China (109)  ·  Germany (50)  ·  Australia (37)  ·  Canada (36)  ·  United Kingdom (33)  ·  France (12)  ·  Japan (12)  ·  Singapore (12)  ·  South Korea (12)  ·  Denmark (11)  ·  Netherlands (10)  ·  Brazil (9)  ·  Egypt (8)  ·  Spain (8)

Top investigators

Joshua R Cook, MD, PhD (7)  ·  Jack A Yanovski, M.D. (5)  ·  John M Jakicic, Ph.D. (4)

Results publications

PMID 12150647, PMID 25919461, PMID 36524539, PMID 36690550, PMID 40576086, PMID 41747885, PMID 10560680, PMID 11245554, PMID 11433905, PMID 12679447, PMID 12841897, PMID 15598683, PMID 15671108, PMID 15681386, PMID 16818482, PMID 16864756, PMID 17065354, PMID 17116758, PMID 17194194, PMID 18310192, PMID 18316660, PMID 18385391, PMID 18400730, PMID 18491071, PMID 18635428, PMID 18825363, PMID 18957534, PMID 19142567, PMID 19244376, PMID 19433800, PMID 19461456, PMID 19475464, PMID 19487105, PMID 19595348, PMID 19635145, PMID 19698154, PMID 19776051, PMID 19796996, PMID 19816674, PMID 19934630, PMID 20194883, PMID 20214807, PMID 20455886, PMID 20457158, PMID 20528109, PMID 20551965, PMID 20725058, PMID 20810979, PMID 20847735, PMID 20881066

NIH funding

2025 (13), 2023 (7), 2019 (5), 2014 (4), 2018 (3), K23DK140614 (3), P30DK063608 (3), 2009 (2), K12DK133995 (2), K23HL103976 (2), K24DK059492 (2), R01DK091748 (2), 1OT2CA297680-01 (1), 2008 (1), 2017 (1)